A Prospective, Multicenter, Non-Interventional Study Evaluating the Bleeding Incidence in Patients With Von Willebrand Disease Undergoing On-Demand Treatment
Latest Information Update: 20 Feb 2025
Price :
$35 *
At a glance
- Drugs Factor VIII/von Willebrand factor (Primary)
- Indications Von Willebrand disease
- Focus Therapeutic Use
- Sponsors Octapharma
- 01 Mar 2021 Status changed from active, no longer recruiting to completed.
- 19 Aug 2020 Planned End Date changed from 1 Dec 2020 to 1 Mar 2021.
- 19 Aug 2020 Planned primary completion date changed from 1 Oct 2020 to 1 Jan 2021.